M. Konstan

发表

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

Matthias Griese, P. Dřevínek, N. McElvaney, 2011, The New England journal of medicine.

Efficacy of the Flutter device for airway mucus clearance in patients with cystic fibrosis.

R. Stern, M. Konstan, C. Doershuk, 1995, The Journal of pediatrics.

Effect of high-dose ibuprofen in patients with cystic fibrosis.

P. J. Byard, C. Hoppel, M. Konstan, 1995, The New England journal of medicine.

Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis.

M. Schluchter, M. Konstan, P. Davis, 2007, American journal of respiratory and critical care medicine.

Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis.

J. Emerson, R. Gibson, M. Rosenfeld, 2001, The Journal of pediatrics.

Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial

A. Chuchalin, M. Konstan, M. Higgins, 2013, Current medical research and opinion.

Infection and inflammation of the lung in cystic fibrosis

M. Konstan, M. Berger, 1993 .

Sputum biomarkers of inflammation in cystic fibrosis lung disease.

M. Konstan, S. Sagel, J. Chmiel, 2007, Proceedings of the American Thoracic Society.

Leukotriene B4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis.

M. Konstan, J. Hilliard, R. Walenga, 1993, The American review of respiratory disease.

Effect of Pseudomonas infection on weight loss, lung mechanics, and cytokines in mice.

B. Erokwu, M. Konstan, P. Davis, 2000, American journal of respiratory and critical care medicine.

Transition to adulthood and adult health care for patients with sickle cell disease or cystic fibrosis: Current practices and research priorities

G. Sawicki, S. McColley, M. Konstan, 2018, Journal of Clinical and Translational Science.

Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection.

J. Clancy, A. Quittner, M. Konstan, 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Clinical care for cystic fibrosis: preparing for the future now.

M. Konstan, P. Flume, 2019, The Lancet. Respiratory medicine.

Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis.

J. Clancy, A. Quittner, M. Konstan, 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes.

M. Konstan, D. VanDevanter, E. Dasenbrook, 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Use of ibuprofen to assess inflammatory biomarkers in induced sputum: Implications for clinical trials in cystic fibrosis.

F. Accurso, B. Ramsey, M. Konstan, 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Normalized T1 Magnetic Resonance Imaging for Assessment of Regional Lung Function in Adult Cystic Fibrosis Patients - A Cross-Sectional Study

P. Jakob, V. Gulani, C. Flask, 2013, PloS one.

Antibiotic and anti-inflammatory therapies for cystic fibrosis.

J. Elborn, M. Konstan, J. Chmiel, 2013, Cold Spring Harbor perspectives in medicine.

Anti-inflammatory therapies for cystic fibrosis lung disease

M. Konstan, 2013 .

Normalized T 1 Magnetic Resonance Imaging for Assessment of Regional Lung Function in Adult Cystic Fibrosis Patients-A Cross-Sectional Study

P. Jakob, V. Gulani, C. Flask, 2013 .

Treatment complexity in cystic fibrosis: trends over time and associations with site-specific outcomes.

G. Sawicki, A. Quittner, M. Konstan, 2013, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Effect of dornase alfa on inflammation and lung function: potential role in the early treatment of cystic fibrosis.

M. Konstan, F. Ratjen, 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Inhaled hypertonic saline in infants and young children with cystic fibrosis.

M. Konstan, E. Dasenbrook, 2012, JAMA.

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.

M. Konstan, P. Flume, M. Kappler, 2011, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial

M. Konstan, G. Angyalosi, P. Minić, 2011, Pediatric pulmonology.

Trends in the use of routine therapies in cystic fibrosis: 1995–2005

W. Morgan, M. Konstan, D. Pasta, 2010, Pediatric pulmonology.

Anti-inflammatory Therapies for Cystic Fibrosis-Related Lung Disease

M. Konstan, D. Nichols, J. Chmiel, 2008, Clinical reviews in allergy & immunology.

Ibuprofen therapy for cystic fibrosis lung disease: revisited

M. Konstan, 2008, Current opinion in pulmonary medicine.

Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects.

C. Hoppel, M. Konstan, P. Davis, 1991, The Journal of pediatrics.

Murine models of CF airway infection and inflammation.

M. Konstan, M. Berger, J. Chmiel, 2002, Methods in molecular medicine.

Anti-Inflammatory Medications for Cystic Fibrosis Lung Disease

M. Konstan, J. Chmiel, 2005, Treatments in respiratory medicine.

A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.

S. McColley, D. Waltz, E. Rietschel, 2014, The Lancet. Respiratory medicine.

An international randomized multicenter comparison of nasal potential difference techniques.

J. Clancy, F. Accurso, F. Vermeulen, 2010, Chest.

Anti‐PcrV antibody in cystic fibrosis: A novel approach targeting Pseudomonas aeruginosa airway infection

F. Accurso, M. Konstan, C. Milla, 2014, Pediatric pulmonology.

Factors influencing outcomes in cystic fibrosis: a center-based analysis.

Charles A. Johnson, S. Butler, W. Morgan, 2003, Chest.

Infant Care Patterns at Epidemiologic Study of Cystic Fibrosis Sites That Achieve Superior Childhood Lung Function

Dave P. Miller, S. McColley, W. Morgan, 2007, Pediatrics.

Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.

J. Clancy, S. Freedman, F. Accurso, 2010, The New England journal of medicine.

A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis.

L. Lands, M. Konstan, S. Heltshe, 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study Design

J. Clancy, G. Sawicki, K. Riekert, 2021, Annals of the American Thoracic Society.

after prolonged treatment of Cystic Fibrosis Patients in Cleveland

L. Rice, R. Bonomo, K. Hujer, 2011 .

Emergence of Linezolid-Resistant Staphylococcus aureus after Prolonged Treatment of Cystic Fibrosis Patients in Cleveland, Ohio

L. Rice, R. Bonomo, K. Hujer, 2011, Antimicrobial Agents and Chemotherapy.

KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa.

F. Accurso, M. Konstan, J. Burns, 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Decline in lung function does not predict future decline in lung function in cystic fibrosis patients

M. Rosenfeld, E. Elkin, W. Morgan, 2015, Pediatric pulmonology.

Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial.

S. Peltz, S. McColley, E. Kerem, 2014, The Lancet. Respiratory medicine.

Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy.

L. Saiman, J. Harris, A. Quittner, 2010, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Design and powering of cystic fibrosis clinical trials using rate of FEV(1) decline as an efficacy endpoint.

M. Konstan, D. Pasta, D. VanDevanter, 2010, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Inflammation and anti-inflammatory therapies for cystic fibrosis.

M. Konstan, J. Chmiel, 2007, Clinics in chest medicine.

The HEALing (Helping to End Addiction Long-term SM) Communities Study: Protocol for a cluster randomized trial at the community level to reduce opioid overdose deaths through implementation of an integrated set of evidence-based practices

Timothy R. Huerta, Darcy A. Freedman, Charles E. Knott, 2020, Drug and Alcohol Dependence.

Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection

C. Goss, J. Clancy, L. Saiman, 2013, Thorax.

Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis.

J. Elborn, M. Konstan, F. Ratjen, 2014, Pulmonary pharmacology & therapeutics.

Preliminary comparison of normalized T1 and non-contrast perfusion MRI assessments of regional lung disease in cystic fibrosis patients.

M. Drumm, Xin Yu, C. Flask, 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Impact of CFTR Modulation on Intestinal pH, Motility, and Clinical Outcomes in Patients With Cystic Fibrosis and the G551D Mutation

E. Tullis, M. Konstan, S. Rowe, 2017, Clinical and Translational Gastroenterology.

The role of inflammation in the pathophysiology of CF lung disease

M. Konstan, M. Berger, J. Chmiel, 2002, Clinical reviews in allergy & immunology.

Inflammatory cytokines in cystic fibrosis lungs.

M. Konstan, T. Bonfield, J. Hilliard, 1995, American journal of respiratory and critical care medicine.

Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa.

M. Konstan, P. Davis, T. Bonfield, 1997, The Journal of clinical investigation.

Longitudinal quantitative low-dose CT in COPD: ready for use?

M. Konstan, T. Haselkorn, J. Wagener, 2013 .

Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation.

G. Sawicki, M. Konstan, P. Flume, 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Relation of sweat chloride concentration to severity of lung disease in cystic fibrosis

M. Schluchter, M. Konstan, P. Davis, 2004, Pediatric pulmonology.

Implementation of the first worldwide quality assurance program for cystic fibrosis multiple mutation detection in population-based screening.

P. Farrell, W. H. Hannon, M. Konstan, 2011, Clinica chimica acta; international journal of clinical chemistry.

Considerations for the Conduct of Clinical Trials with Antiinflammatory Agents in Cystic Fibrosis. A Cystic Fibrosis Foundation Workshop Report.

F. Accurso, M. Konstan, F. Ratjen, 2015, Annals of the American Thoracic Society.

Elastin and collagen degradation products in urine of patients with cystic fibrosis.

M. Konstan, H. Dorkin, G. Snider, 1995, American journal of respiratory and critical care medicine.

Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis.

M. Konstan, P. Burfeind, T. Bonfield, 1995, American journal of respiratory cell and molecular biology.

Beta 2 adrenergic receptor polymorphisms in cystic fibrosis

M. Schluchter, M. Drumm, K. Goddard, 2005, Pediatric pulmonology.

Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function

W. Morgan, M. Konstan, M. Schechter, 2007, Pediatric pulmonology.

Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. Implications for antiinflammatory therapy in cystic fibrosis.

M. Konstan, P. Davis, K. Vargo, 1990, The American review of respiratory disease.

Patterns of medical practice in cystic fibrosis: Part II. Use of therapies

S. Butler, W. Morgan, M. Konstan, 1999, Pediatric pulmonology.

Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF).

E. Kerem, M. Konstan, I. Sermet-Gaudelus, 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Rapid intravenous desensitization to colistin.

M. Konstan, M. Tosi, V. Paschall, 2012, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Cross-sectional and longitudinal studies of naturally occurring antibodies to Pseudomonas aeruginosa in cystic fibrosis indicate absence of antibody-mediated protection and decline in opsonic quality after infection.

R. Stern, M. Konstan, J. Schreiber, 1995, The Journal of infectious diseases.

Transfer of the human Alpha1-antitrypsin gene into pulmonary macrophages in vivo.

J. C. Perales, M. Konstan, A. Ziady, 1998, American journal of respiratory cell and molecular biology.

Novel tobramycin inhalation powder in cystic fibrosis subjects: Pharmacokinetics and safety

M. Konstan, C. Conrad, D. Geller, 2007, Pediatric pulmonology.

Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis.

M. Konstan, P. Davis, 2002, Advanced drug delivery reviews.

Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: Results of a phase I multi‐center study

R. Gibson, F. Accurso, B. Ramsey, 2001, Pediatric pulmonology.

Inflammatory mediators in CF patients.

M. Konstan, P. Davis, J. Hilliard, 2002, Methods in molecular medicine.

Altered respiratory epithelial cell cytokine production in cystic fibrosis.

M. Konstan, T. Bonfield, M. Berger, 1999, The Journal of allergy and clinical immunology.

Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis.

M. Konstan, S. Heltshe, J. Hilliard, 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Association of High‐Dose Ibuprofen Use, Lung Function Decline, and Long‐Term Survival in Children with Cystic Fibrosis

G. Sawicki, W. Morgan, M. Konstan, 2018, Annals of the American Thoracic Society.

Cystic fibrosis clinical characteristics associated with dornase alfa treatment regimen change

W. Morgan, M. Konstan, D. Pasta, 2018, Pediatric pulmonology.

Lung function decline is delayed but not decreased in patients with cystic fibrosis and the R117H gene mutation.

C. Goss, G. Sawicki, W. Morgan, 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.

C. Goss, G. Sawicki, D. Waltz, 2017, The Lancet. Respiratory medicine.

Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function.

W. Morgan, M. Konstan, D. Pasta, 2016, The Journal of pediatrics.

Efficacy response in CF patients treated with ivacaftor: Post‐hoc analysis

J. Elborn, M. Konstan, S. Rodriguez, 2015, Pediatric pulmonology.

Lessons learned from a randomized trial of airway secretion clearance techniques in cystic fibrosis

R. Castile, A. Quittner, F. Accurso, 2010, Pediatric pulmonology.

The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis.

L. Saiman, M. Konstan, J. Blumer, 2005, Chest.

Estimating effectiveness in an observational study: a case study of dornase alfa in cystic fibrosis. The Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis.

S. Butler, W. Morgan, M. Konstan, 1999, The Journal of pediatrics.

A randomized placebo-controlled trial of ataluren for the treatment of nonsense mutation cystic fibrosis

S. Peltz, S. McColley, F. Accurso, 2014 .

Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis.

W. Morgan, M. Konstan, L. Rasouliyan, 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Standardized procedure for measurement of nasal potential difference: An outcome measure in multicenter cystic fibrosis clinical trials

J. Emerson, M. Knowles, M. Konstan, 2004, Pediatric pulmonology.

Safety, tolerability, and plasma exposure of tiotropium Respimat® in children and adults with cystic fibrosis.

M. Konstan, P. Moroni-Zentgraf, P. Koker, 2015, Journal of aerosol medicine and pulmonary drug delivery.

Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis.

Charles A. Johnson, Robert A. Matousek, S. Butler, 2003, The Journal of pediatrics.

Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis.

W. Morgan, M. Konstan, D. Pasta, 2008, The Journal of pediatrics.

The use of anti-inflammatory medications in cystic fibrosis: trends and physician attitudes.

M. Sockrider, M. Konstan, C. Oermann, 1999, Chest.

Therapies aimed at airway inflammation in cystic fibrosis.

M. Konstan, 1998, Clinics in chest medicine.

Characterizing aggressiveness and predicting future progression of CF lung disease.

M. Konstan, D. VanDevanter, J. Wagener, 2009, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries.

G. Sawicki, S. Charman, M. Konstan, 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Shifting patterns of inhaled antibiotic use in cystic fibrosis

M. Konstan, S. Moskowitz, D. Pasta, 2008, Pediatric pulmonology.

Prolonged inflammatory response to acute Pseudomonas challenge in interleukin-10 knockout mice.

M. Konstan, H. Lester Kirchner, M. Berger, 2002, American journal of respiratory and critical care medicine.

Forming Cardi-OH: A Statewide Collaborative to Improve Cardiovascular Health in Ohio

E. Beverly, Jackson T. Wright, A. Perzynski, 2022, Cureus.

Human lung lysozyme: sources and properties.

T. Boat, M. Konstan, R. Wood, 1981, The American review of respiratory disease.

Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary function.

W. Morgan, M. Konstan, D. Pasta, 2013, The Journal of pediatrics.

Pulmonary exacerbations in cystic fibrosis

Charles A. Johnson, S. Butler, M. Konstan, 2004, Pediatric pulmonology.

Inflammation in the cystic fibrosis lung

M. Konstan, J. Chmiel, 2016 .

Erratum: Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation (American Journal of Respiratory and Critical Care Medicine (1994) 150 (448-454))

M. Konstan, M. Berger, K. A. Hilliard, 1995 .

Efficacy of the Flutter device for airway mucus clearance in patients with cystic fibrosis.

R. Stern, M. Konstan, C. Doershuk, 1995, Jornal de Pediatria.

The pathologic characteristics of interstitial pneumonia cystic fibrosis. A retrospective autopsy study.

J. Tomashefski, M. Konstan, C. Abramowsky, 1989, American journal of clinical pathology.

Clinical use of dornase alfa is associated with a slower rate of FEV1 decline in cystic fibrosis

W. Morgan, M. Konstan, D. Pasta, 2011, Pediatric pulmonology.

Dornase alfa and progression of lung disease in cystic fibrosis

M. Konstan, 2008 .

BMI fails to identify poor nutritional status in stunted children with CF.

W. Morgan, M. Konstan, D. Pasta, 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Tissue-Specific Fc γ and Complement Receptor Expression by Alveolar Macrophages Determines Relative Importance of IgG and Complement in Promoting Phagocytosis of Pseudomonas aeruginosa

M. Konstan, J. Schreiber, M. Berger, 1994, Pediatric Research.

Clinical use of tobramycin inhalation solution (TOBI®) shows sustained improvement in FEV1 in cystic fibrosis

W. Morgan, M. Konstan, D. Pasta, 2014, Pediatric pulmonology.

Location and duration of treatment of cystic fibrosis respiratory exacerbations.

W. Morgan, M. Konstan, M. Schechter, 2011, American journal of respiratory and critical care medicine.

Patterns of medical practice in cystic fibrosis: Part I. Evaluation and monitoring of health status of patients

S. Butler, W. Morgan, M. Konstan, 1999, Pediatric pulmonology.

Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del‐CFTR

S. McColley, D. Waltz, E. Rietschel, 2017, Annals of the American Thoracic Society.

Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis.

N. Morris, M. Konstan, P. Flume, 2016, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Increasing life expectancy in cystic fibrosis: Advances and challenges

M. Konstan, P. Davis, K. McBennett, 2021, Pediatric pulmonology.

Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor

G. Sawicki, M. Konstan, D. Bilton, 2018, Thorax.

Patients with Cystic Fibrosis and a G551D or Homozygous F508del Mutation: Similar Lung Function Decline.

G. Sawicki, M. Konstan, D. Pasta, 2017, American journal of respiratory and critical care medicine.

Building global development strategies for cf therapeutics during a transitional cftr modulator era.

C. Goss, P. Dřevínek, S. Donaldson, 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study.

M. Konstan, S. Rowe, E. Zemanick, 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Treatment of airway inflammation in cystic fibrosis.

M. Konstan, 1996, Current opinion in pulmonary medicine.

Relationship of Antibiotic Treatment to Recovery after Acute FEV1 Decline in Children with Cystic Fibrosis

W. Morgan, M. Konstan, D. Pasta, 2017, Annals of the American Thoracic Society.

Pulmonary exacerbations in cystic fibrosis: Young children with characteristic signs and symptoms

E. Elkin, W. Morgan, M. Konstan, 2013, Pediatric pulmonology.

IL-10 attenuates excessive inflammation in chronic Pseudomonas infection in mice.

M. Konstan, T. Bonfield, D. Dawson, 1999, American journal of respiratory and critical care medicine.

Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation.

M. Konstan, M. Berger, M W Konstan, 1994, American journal of respiratory and critical care medicine.

Opportunities for life course research through the integration of data across Clinical and Translational Research Institutes

J. Tobin, M. Karagas, H. Hanson, 2018, Journal of clinical and translational science.

Safety and Preliminary Clinical Activity of a Novel Pancreatic Enzyme Preparation in Pancreatic Insufficient Cystic Fibrosis Patients

C. Goss, T. Mahl, M. Konstan, 2006, Pancreas.

Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national sample

G. Sawicki, A. Quittner, M. Konstan, 2012, Quality of Life Research.

Risk factors for rate of decline in FEV1 in adults with cystic fibrosis.

W. Morgan, M. Konstan, D. Pasta, 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Genetic modifiers of lung disease in cystic fibrosis.

Michael R Knowles, Fei Zou, Fred A Wright, 2005, The New England journal of medicine.

Cystic fibrosis.

M. Drumm, M. Konstan, P. Davis, 1996, American journal of respiratory and critical care medicine.

Effect of Ibuprofen on Neutrophil Migration in Vivo in Cystic Fibrosis and Healthy Subjects

C. Hoppel, M. Konstan, P. Davis, 2003, Journal of Pharmacology and Experimental Therapeutics.

Genomic heterogeneity underlies multidrug resistance in Pseudomonas aeruginosa: A population-level analysis beyond susceptibility testing

Nikhil P. Krishnan, R. Bonomo, Jacquelynn Benjamino, 2022, PloS one.

Lung function decline from adolescence to young adulthood in cystic fibrosis

Rory L. Michaelis, S. McColley, W. Morgan, 2012, Pediatric pulmonology.

Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis.

C. Merlo, M. Konstan, M. Boyle, 2010, JAMA.

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

Xiaohong Huang, Michael P Boyle, Carla Colombo, 2015, The New England journal of medicine.

What Is Cystic Fibrosis?

M. Konstan, T. Endres, 2022, JAMA.

Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy.

M. Konstan, A. Cantin, D. Hartl, 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

A comparative study of lysozyme and its secretion by tracheal epithelium.

T. Boat, M. Konstan, P. Cheng, 1982, Experimental lung research.

Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution.

S. L. Hyatt, Osman Muhammad, R. Stern, 2004, Human gene therapy.

Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.

J. Emerson, R. Gibson, M. Rosenfeld, 2003, American journal of respiratory and critical care medicine.

Healthcare resource utilization and costs among children with cystic fibrosis in the United States

M. Konstan, M. Bonafede, B. Limone, 2021, Pediatric pulmonology.

Impact of pregnancy on women with cystic fibrosis.

W. Morgan, M. Konstan, P. Frederick, 2006, Chest.

Coefficients of fat and nitrogen absorption in healthy subjects and individuals with cystic fibrosis.

M. Konstan, L. Hendeles, D. Borowitz, 2007, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG.

Ultrase MT12 and Ultrase MT20 in the treatment of exocrine pancreatic insufficiency in cystic fibrosis: safety and efficacy

R. Stern, M. Konstan, M. E. Wohl, 2004, Alimentary pharmacology & therapeutics.

Reopening Schools Safely: The Case for Collaboration, Constructive Disruption of Pre-Coronavirus 2019 Expectations, and Creative Solutions

L. Ross, C. Byington, L. Guay-Woodford, 2020, The Journal of Pediatrics.

Study of a novel pancreatic enzyme replacement therapy in pancreatic insufficient subjects with cystic fibrosis.

C. Goss, A. Quittner, M. Konstan, 2006, The Journal of pediatrics.

BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs.

G. Pier, M. Tunney, T. Wagner, 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Year-to-year changes in lung function in individuals with cystic fibrosis.

E. Elkin, T. Liou, W. Morgan, 2010, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Rare loss of function variants in candidate genes and risk of colorectal cancer

Taylor J. Maxwell, Jennifer G. Robinson, Andrew J. Sanford, 2018, Human Genetics.

Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis.

R. Tal-Singer, E. Kerem, J. Pilewski, 2013, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis.

D. Waltz, J. Elborn, B. Ramsey, 2016, The Lancet. Respiratory medicine.

Treatment Setting and Outcomes of Cystic Fibrosis Pulmonary Exacerbations

W. Morgan, M. Konstan, D. Pasta, 2017, Annals of the American Thoracic Society.

IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis.

N. Morris, M. Konstan, D. VanDevanter, 2016, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis.

M. Konstan, D. Pasta, D. VanDevanter, 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis

J. Emerson, R. Gibson, M. Rosenfeld, 2013, Pediatric pulmonology.

Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis

W. Morgan, M. Konstan, D. Pasta, 2013, Pediatric pulmonology.

Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint.

W. Morgan, M. Konstan, D. Pasta, 2011, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations

M. O'riordan, M. Konstan, J. Blumer, 2010, Respiratory research.

Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis.

Charles A. Johnson, S. Butler, W. Morgan, 2007, The Journal of pediatrics.

Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST).

Ying Jiang, Barry Plant, Matthias Griese, 2014, The Lancet. Respiratory medicine.

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation

J. Clancy, M. Ballmann, F. Accurso, 2011, Thorax.

Long-term effects of pregnancy and motherhood on disease outcomes of women with cystic fibrosis.

A. Quittner, M. Konstan, D. Pasta, 2013, Annals of the American Thoracic Society.

Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data.

G. Sawicki, M. Konstan, D. Pasta, 2015, American journal of respiratory and critical care medicine.

Erratum to: Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national, US sample

G. Sawicki, A. Quittner, M. Konstan, 2012, Quality of Life Research.

Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1.

S. McColley, D. Waltz, B. Ramsey, 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data.

J. Clancy, F. van Goor, F. Accurso, 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Antibiotic treatment of signs and symptoms of pulmonary exacerbations: A comparison by care site

M. Rosenfeld, G. Sawicki, W. Morgan, 2015, Pediatric pulmonology.

Epidemiologic Study of Cystic Fibrosis: 25 years of observational research

W. Morgan, M. Konstan, D. Pasta, 2021, Pediatric pulmonology.

Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis.

S. McColley, M. Konstan, M. Schechter, 2009, The Journal of pediatrics.

Epidemiologic study of cystic fibrosis: Design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada

Charles A. Johnson, S. Butler, W. Morgan, 1999, Pediatric pulmonology.

Highlights of a workshop to discuss targeting inflammation in cystic fibrosis.

S. Randell, E. Gulbins, D. Waltz, 2009, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Classifying severity of cystic fibrosis lung disease using longitudinal pulmonary function data.

M. Schluchter, M. Drumm, M. Knowles, 2006, American journal of respiratory and critical care medicine.

Behavioral and nutritional treatment for preschool-aged children with cystic fibrosis: a randomized clinical trial.

R. Szczesniak, J. Clancy, S. Powers, 2015, JAMA pediatrics.

Behavioral and Nutritional Treatment for Preschool-Aged ChildrenWith Cystic Fibrosis

J. Clancy, J. Rausch, R. Castile, 2015 .

Study design considerations for evaluating the efficacy and safety of pancreatic enzyme replacement therapy in patients with cystic fibrosis.

R. Kronmal, W. Morgan, B. Ramsey, 2013, Clinical investigation.

Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease.

M. Konstan, D. VanDevanter, 2012, Clinical investigation.

Comparison of FEV1 reference equations for evaluating a cystic fibrosis therapeutic intervention

W. Morgan, M. Konstan, D. Pasta, 2017, Pediatric pulmonology.

A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities.

J. P. Sy, H. Tiddens, J. Sy, 2001, The Journal of pediatrics.

Association between pulmonary function and sputum biomarkers in cystic fibrosis.

R. Kronmal, F. Accurso, B. Ramsey, 2007, American journal of respiratory and critical care medicine.

Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients

Mark D Schluchter, M. Schluchter, M. Konstan, 2002, Statistics in medicine.

Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor

T. Liou, M. Konstan, A. Ward, 2019, Therapeutic advances in respiratory disease.

Non-viral gene transfer therapy for cystic fibrosis

M. Konstan, P. Davis, A. Ziady, 2003, Expert opinion on biological therapy.

A multi‐center controlled trial of growth hormone treatment in children with cystic fibrosis

M. Konstan, B. Bakker, B. Lippe, 2012, Pediatric pulmonology.

Identifying Treatments That Halt Progression of Pulmonary Disease in Cystic Fibrosis

P. J. Byard, M. Konstan, P. Davis, 1997, Pediatric Research.

Pulmonary outcome prediction (POP) tools for cystic fibrosis patients

E. Elkin, W. Morgan, M. Konstan, 2010, Pediatric pulmonology.

Current understanding of the inflammatory process in cystic fibrosis: Onset and etiology

Melvin Berger, M. Konstan, Michael W. Konstan, 1997, Pediatric pulmonology.

Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis.

E. Springman, S. Aaron, V. Lucidi, 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Trends in the clinical characteristics of the U.S. cystic fibrosis patient population from 1995 to 2005

W. Morgan, M. Konstan, L. Rasouliyan, 2008, Pediatric pulmonology.

Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis

J. Emerson, R. Gibson, F. Accurso, 2007, Pediatric pulmonology.

112 Analysis of long-term use of liposomal amikacin for inhalation (LAI) in patients with cystic fibrosis (CF) who have chronic infection from Pseudomonas aeruginosa

J. Clancy, L. Dupont, M. Konstan, 2015 .

42 Tobramycin powder for inhalation is effective in advanced stage CF lung disease: the EAGER trial

G. Bader, M. Konstan, G. Angyalosi, 2014 .

ANALYSIS OF LONG-TERM LIPOSOMAL AMIKACIN FOR INHALATION IN PATIENTS WITH CYSTIC FIBROSIS AND CHRONIC INFECTION FROM PSEUDOMONAS AERUGINOSA

J. Clancy, L. Dupont, M. Konstan, 2014 .

82* Microbiological and clinical response to tobramycin inhalation powder (TIP(tm)) in cystic fibrosis patients with chronic Pseudomonas aeruginosa (Pa) infection

M. Konstan, P. Flume, M. Higgins, 2011 .

Treatment convenience and satisfaction of tobramycin inhalation powder (TIP) versus TOBI in cystic fibrosis (CF) patients

M. Konstan, P. Flume, G. Angyalosi, 2010 .

Safety and efficacy of tobramycin inhalation powder (TIP) in treating CF patients infected with Pseudomonas aeruginosa (Pa)

M. Konstan, P. Flume, G. Angyalosi, 2010 .

Effective treatment of chronic Pseudomonas aeruginosa (Pa) infection with tobramycin inhalation powder in CF patients

M. Konstan, G. Angyalosi, P. Minić, 2009 .

Tobramycin Inhalation Powder Is Effective and Safe in the Treatment of Chronic PulmonaryPseudomonas aeruginosa (Pa)Infection in Patients with Cystic Fibrosis.

M. Konstan, G. Angyalosi, F. Brockhaus, 2009, ATS 2009.

Early childhood wheezing is associated with lower lung function in cystic fibrosis

M. Rosenfeld, W. Morgan, M. Konstan, 2012, Pediatric pulmonology.

Pulmonary function outcomes for assessing cystic fibrosis care.

E. Elkin, W. Morgan, M. Konstan, 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995-2005.

E. Elkin, W. Morgan, M. Konstan, 2013, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis *

N. McCarty, M. Konstan, T. Kelley, 2002, Pediatric pulmonology.

Acute loxapine intoxication in a child.

M. Konstan, I. Sunshine, R. Solano, 1982, Journal of Analytical Toxicology.

Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis

W. Morgan, M. Konstan, D. Pasta, 2019, Pediatric pulmonology.

Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D-CFTR Mutation Treated With VX-770, An Investigational Oral Potentiator Of CFTR

J. Clancy, F. Accurso, M. Ashlock, 2010, ATS 2010.

Final results of a 14- and 28-day study of VX-770 in subjects with CF

J. Clancy, S. Freedman, F. Accurso, 2009 .

Improvement in ion transport biomarkers and spirometry with the investigational CFTR potentiator VX-770 in subjects with cystic fibrosis and the G551D-CFTR mutation

J. Clancy, F. Accurso, J. Pilewski, 2010 .

WS3.1 The effect of ivacaftor on the rate of lung function decline in CF patients with a G551D-CFTR mutation

G. Sawicki, M. Konstan, D. Pasta, 2014 .

Risk factors for mortality before age 18 years in cystic fibrosis

S. McColley, W. Morgan, M. Konstan, 2017, Pediatric pulmonology.

143 Lumacaftor/ivacaftor combination therapy in CF patients homozygous for F508del-CFTR with severe lung dysfunction

D. Waltz, J. Elborn, B. Ramsey, 2015 .

Risk factors for onset of persistent respiratory symptoms in children with cystic fibrosis

S. McColley, M. Konstan, D. Pasta, 2012, Pediatric pulmonology.

WS01.3 Lumacaftor in combination with ivacaftor in patients with cystic fibrosis who are homozygous for the F508del-CFTR mutation

D. Waltz, J. Elborn, B. Ramsey, 2015 .

WS7.4 Lumacaftor, an investigational CFTR corrector, in combination with ivacaftor, a CFTR potentiator, in CF patients with the F508del-CFTR mutation: Phase 2 interim analysis

S. Colley, D. Waltz, S. Bell, 2013 .

Effect of smaller droplet size of dornase alfa on lung function in mild cystic fibrosis

Charles A. Johnson, M. Konstan, H. Eigen, 1998, Pediatric pulmonology.

Rate of Lung Function Decline in People with Cystic Fibrosis Having a Residual Function Gene Mutation

C. Goss, G. Sawicki, W. Morgan, 2022, Pulmonary Therapy.

Liver Involvement in the Hispanic Population of North America With Cystic Fibrosis

W. Morgan, M. Konstan, D. Pasta, 2014, Journal of pediatric gastroenterology and nutrition.

The Role of Inhaled Corticosteroids in the Management of Cystic Fibrosis

M. Konstan, K. Ross, J. Chmiel, 2009, Paediatric drugs.

Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis * *

N. McCarty, M. Konstan, T. Kelley, 2002, Pediatric pulmonology.

One‐year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis

M. Konstan, P. Flume, G. Angyalosi, 2016, Pediatric pulmonology.

Pseudomonas cepacia-associated pneumonia in cystic fibrosis. Relation of clinical features to histopathologic patterns of pneumonia.

R. Stern, J. Tomashefski, H. Goldberg, 1988, Archives of pathology & laboratory medicine.

Efficacy and Safety of a New Formulation of Pancrelipase (Ultrase MT20) in the Treatment of Malabsorption in Exocrine Pancreatic Insufficiency in Cystic Fibrosis

T. Liou, M. Konstan, J. Kanga, 2010, Gastroenterology research and practice.

Socioeconomic status and the likelihood of antibiotic treatment for signs and symptoms of pulmonary exacerbation in children with cystic fibrosis.

S. McColley, W. Morgan, M. Konstan, 2011, The Journal of pediatrics.

Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials

M. Konstan, J. Mcintosh, D. VanDevanter, 2020, Journal of Cystic Fibrosis.

Pulmonary exacerbations and acute declines in lung function in patients with cystic fibrosis.

W. Morgan, M. Konstan, D. Pasta, 2018, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective.

J. Pilewski, S. Donaldson, M. Konstan, 2023, The Lancet. Respiratory medicine.

Long-Term Impact of Ivacaftor on Healthcare Resource Utilization Among People with Cystic Fibrosis in the United States

M. Konstan, M. Bonafede, B. Limone, 2021, Pulmonary Therapy.

BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs.

G. Pier, M. Tunney, M. Konstan, 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation

F. Accurso, M. Ashlock, M. Konstan, 2012 .

HER2-Neuregulin Mediated IL-8 Release In Cystic Fibrosis

M. Konstan, J. Kern, T. Bonfield, 2011, ATS 2011.

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.

M. Konstan, P. Flume, M. Kappler, 2011, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial

M. Konstan, G. Angyalosi, P. Minić, 2011, Pediatric pulmonology.

WS5.6 A challenging double-blind, placebo-controlled study of tobramycin inhalation powder in cystic fibrosis: results of the EDIT trial

A. Chuchalin, M. Konstan, M. Higgins, 2012 .

Shifting patterns of inhaled antibiotic use in cystic fibrosis

M. Konstan, S. Moskowitz, D. Pasta, 2008, Pediatric pulmonology.

Trends in the clinical characteristics of the U.S. cystic fibrosis patient population from 1995 to 2005

W. Morgan, M. Konstan, L. Rasouliyan, 2008, Pediatric pulmonology.

A pipeline of therapies for cystic fibrosis.

C. Penland, M. Ashlock, B. Ramsey, 2009, Seminars in respiratory and critical care medicine.

Effects of the Communities that Heal (CTH) intervention on perceived opioid-related community stigma in the HEALing Communities Study: results of a multi-site, community-level, cluster-randomized trial

Timothy R. Huerta, A. McAlearney, N. El-Bassel, 2024, The Lancet Regional Health - Americas.

Efficacy and safety of LAU-7b in a Phase 2 trial in adults with cystic fibrosis.

M. Konstan, E. Matouk, J. Chmiel, 2024, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

ePS03.4 Improved rate of decline in percent predicted FEV1 (ppFEV1) is not associated with acute improvement in ppFEV1 in patients with cystic fibrosis (CF) treated with ivacaftor

G. Sawicki, M. Konstan, D. Pasta, 2016 .

94 The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis

S. Peltz, E. Kerem, F. Accurso, 2014 .

WS7.5 Interim results of the phase 3 open-label study of ataluren in nonsense mutation cystic fibrosis (nmCF)

S. Peltz, E. Kerem, F. Accurso, 2013 .

Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor: A secondary analysis

M. Konstan, S. Rodriguez, A. Munck, 2013 .

63 The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease

S. Peltz, E. Kerem, F. Accurso, 2013 .

Long-term effects of pregnancy and motherhood on disease outcomes of women with cystic fibrosis.

A. Quittner, M. Konstan, D. Pasta, 2013, Annals of the American Thoracic Society.

A Medicaid Statewide Hypertension Quality Improvement Project: Initial Results

D. Einstadter, A. Perzynski, S. Bolen, 2023, Cureus.

The continuing need for dornase alfa for extracellular airway DNA hydrolysis in the era of CFTR modulators.

M. Konstan, E. Roesch, Abdelkader Rahmaoui, 2024, Expert review of respiratory medicine.